In this study, the combined treatment of ursolic acid and resveratrol was evaluated for its inhibitory effects on skin tumor promotion in female FVB mice. The combination was applied topically before TPA treatment and was found to significantly inhibit TPA-induced epidermal hyperproliferation, signaling pathways, and skin inflammation more effectively than either compound alone. Key signaling pathways affected included EGFR, STAT3, and NF-κB, among others. The combination also increased tumor suppressor levels and reduced proinflammatory cytokine expression. Overall, the combined treatment resulted in a greater reduction in tumor multiplicity and size, highlighting its potential as a more effective strategy for preventing skin tumor promotion compared to individual treatments.
March 2014 in “Journal of The American Academy of Dermatology” Tavaborole is a safe and effective toenail fungus treatment, with the 5% solution being the best option.
In this study, the combined treatment of ursolic acid and resveratrol was evaluated for its effects on skin tumor promotion in female FVB mice. The combination was applied topically before TPA treatment and was found to significantly inhibit TPA-induced epidermal hyperproliferation, signaling pathways, and skin inflammation more effectively than either compound alone. Key signaling pathways affected included EGFR, STAT3, and NF-κB, among others. The combination also increased tumor suppressor levels and reduced proinflammatory cytokine expression. Overall, the combined treatment resulted in a greater reduction in tumor multiplicity and size, highlighting its potential as a more effective strategy for inhibiting skin tumor promotion compared to individual treatments.
3 citations
,
August 2023 in “Drug safety” This source reports that trastuzumab deruxtecan improves outcomes in HER2-positive and HER2-low metastatic breast cancer, emphasizing the need for careful adverse event monitoring, particularly for interstitial lung disease, and managing emetic risk to maximize benefits.
April 2023 in “Journal of The American Academy of Dermatology” This study investigated the association between hair loss and medications affecting the GH/IGF-1 pathway, using the FDA Adverse Event Reporting System to analyze reporting odds ratios of alopecia.
15 citations
,
November 2020 in “Pharmaceutics” In this ex vivo and mouse model study, Tofacitinib-loaded nanoparticles demonstrated enhanced delivery of the drug into hair follicles and reduced inflammatory effects compared to conventional forms, indicating potential for safer, topical use in treating alopecia areata.
1 citations
,
February 2022 in “Clinical, Cosmetic and Investigational Dermatology” In this study, researchers found that the thyroxine receptor agonist TDM10842 accelerated the onset of anagen, a hair growth phase, in C3H mice, potentially through activation of the Wnt/beta-catenin and Hedgehog pathways, with Pclaf playing a key role in this process.
March 2026 in “Voprosy dermatologii i venerologii/Dermatologiâ ža̋ne veneralogiâ ma̋selelerì” This literature review highlights the critical importance of early dermatological diagnosis of tuberous sclerosis, focusing on its genetic basis, dermatological markers, and the role of genetic testing and multidisciplinary support, while discussing treatment options like mTOR inhibitors and their limitations.
January 2016 in “The Australian Pharmacist” Tofacitinib might be used to treat hair loss.
1 citations
,
January 2001 This study observed that cancer patients had significantly lower immunity and higher virus infection and zinc levels in hair compared to those with benign tumors and healthy subjects.
![Discovery of 7-Methoxy-6-[4-(4-Methyl-1,3-Thiazol-2-yl)-1H-Imidazol-5-yl]-1,3-Benzothiazole (TASP0382088): A Potent and Selective Transforming Growth Factor-β Type I Receptor Inhibitor as a Topical Drug for Alopecia](/images/assets/9620bd26-3366-4f2a-bcac-f511697bbc41/small/35997.jpg)
6 citations
,
January 2013 in “Chemical & pharmaceutical bulletin/Chemical and pharmaceutical bulletin” In this study, TASP0382088 showed potent selective inhibition of the ALK5 receptor, significantly reducing Smad2 phosphorylation in mouse skin following topical application.
January 2023 in “Marmara University Open Access System” This study found that tideglusib delivered topically in a bacterial cellulose hydrogel showed positive effects on the wound healing of rat palatal mucosa, as observed through macroscopic, histomorphometric, and immunohistochemical evaluations.
January 2025 in “International Journal of Dermatology” This case report describes a patient with eruptive tumor of follicular infundibulum, emphasizing the need for dermatologists to include it in the differential diagnosis of acquired facial hypopigmentation.
26 citations
,
July 2006 in “International Journal of Cosmetic Science” This study found that taurine uptake by isolated human hair follicles promoted hair survival and protected against TGF-β1-induced damage in an in vitro setting.
13 citations
,
November 2021 in “Pediatric Dermatology” This study found that oral tofacitinib was effective and well tolerated for treating alopecia areata in most pediatric patients, with nearly 73% experiencing hair regrowth.
2 citations
,
September 2024 in “PLoS ONE” This study suggests that combining bendamustine with tucidinostat may improve survival in patients with relapsed or refractory adult T-cell leukemia/lymphoma, highlighting its potential for clinical investigation.
18 citations
,
November 2017 in “JoLS Journal of Life Sciences” This study investigates the effects of Tenebrio molitor as a novel biomaterial for preventing alopecia and promoting hair growth, but reports no conclusive results.
409 citations
,
May 1991 in “Genes & Development” This study observed that overexpression of TGF-alpha in transgenic mice led to thicker epidermis and stunted hair growth, particularly in regions with normally thick skin and low hair density.
March 2010 in “European Journal of Cancer Supplements” 1 citations
,
March 2021 in “Journal of Investigative Dermatology” Sirolimus can reduce tumor cell size in TSC-related skin tumors, but continuous treatment is needed to maintain benefits.
July 2020 in “Stem Cells Translational Medicine” In this study, Caplan et al. found that treatment with human Tregs expanded from umbilical cord blood may modulate immune responses and improve outcomes in a rodent model of traumatic brain injury.
12 citations
,
February 2014 in “PLoS ONE” This study observed high expression of mTOR pathway effectors in fibrous papules and TSC-associated angiofibromas, suggesting that topical rapamycin might be an effective treatment for fibrous papules.
51 citations
,
June 2016 in “Journal of the European Academy of Dermatology and Venereology” In this study, tofacitinib treatment was associated with significant hair regrowth in two patients with alopecia universalis over eight months, with minimal adverse effects reported.
April 2018 in “Journal of Investigative Dermatology” In this first-in-human study, BLZ-100, an intraoperative fluorescent imaging agent, was administered to 21 patients before skin cancer surgery and was found to be well tolerated without serious adverse effects, suggesting its potential to help distinguish cancerous from non-cancerous tissue based on fluorescence.
51 citations
,
December 2003 in “The FASEB Journal” This study reports that AS101 induced hair growth in mice and suggests potential for treating chemotherapy-induced alopecia in humans, which was observed in case report studies with three adolescents.
44 citations
,
September 2014 in “Cell Death & Differentiation” This review discusses the role of tumor suppressors in controlling tumor-associated inflammation and suggests that targeting this inflammation may counteract the effects of tumor suppressor loss.
July 2025 in “Ultrasound in Medicine & Biology” This study found that nanobubble-encapsulated diclofenac with ultrasound-targeted microbubble destruction (DNBs-UTMD) can enhance the anti-tumor efficacy of Doxil® by regulating the tumor immune microenvironment, improving drug uptake, and increasing T cell responses while reducing immune-suppressive cells in the process.
28 citations
,
October 2010 in “Targeted Oncology” This case report presents an instance of tufted hair folliculitis in a woman treated with trastuzumab, highlighting a previously unreported skin side effect of this selective HER2 inhibitor.
2 citations
,
January 2025 in “Сибирский научный медицинский журнал” In this study using a mouse model, the authors reported that the synthetic antioxidant TS-13 effectively inhibited tumor growth comparably to doxorubicin and reduced chemotherapy side effects, such as weight loss, splenotoxicity, and alopecia, more effectively when combined with the cytostatic treatment.
3 citations
,
May 2008 in “Journal of Clinical Oncology” This study found that Pmab treatment may alter hair follicle growth cycles, leading to trichomegaly and hypertrichosis, but these effects do not correlate with other skin toxicities.